drugset / Trial / NCT01373684
PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This study intends to investigate whether addition of PEG-IFN alfa-2a in HBeAg-negative chronic hepatitis B patients who are pretreated with nucleos(t)ide analogues enhances the degree of HBsAg decline.
Timeline
- Start
- 2012-05-25
- Primary completion
- 2019-10-28
- Completion
- 2019-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Comparator | Adefovir | Unknown | — | — |
| Comparator | Entecavir | Small molecule | — | — |
| Comparator | Tenofovir | Small molecule | — | — |